Latest Histone deacetylase Stories
WALTHAM, Mass., Oct.
Heart muscle cells do not normally replicate in adult tissue, but multiply with abandon during development.
SINGAPORE, Sept. 27 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate cancer (HRPC).
WALTHAM, Mass., Aug. 11 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that it has issued $6M in convertible notes and warrants to its Series A investors bringing the total investment to date to $55M.
WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July 27 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Shape Pharmaceuticals announced today that they have entered into a partnership to advance Shape's novel, topical treatment for cutaneous T-Cell lymphoma (CTCL) into clinical development.
WALTHAM, Mass., May 24 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics company, announced today that abstracts related to its lead anti-cancer compound, entinostat, an orally bioavailable, selective, class I histone deacetylase (HDAC) inhibitor, will be presented at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. "The data and information we are presenting at the Annual ASCO Meeting support entinostat's promise in combination...
The world's scientific community may be one step closer to understanding age-related memory loss, and to developing a drug that might help boost memory.
In studies on cancer, heart disease, neurological disorders and other degenerative conditions, some scientists are moving away from the â€œnature-versus-nurtureâ€ debate and are finding youâ€™re not a creature of either genetics or environment, but both â€“ with enormous implications for a new approach to health.
SUNNYVALE, Calif., April 15 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced multiple presentations covering its Btk and HDAC programs at the American Association for Cancer Research (AACR) 2010 Annual Meeting being held April 17-21 in Washington, DC.
Collaboration Exploits Cellzome's World-Leading Proteomics Technology in Epigenetics CAMBRIDGE, England and HEIDELBERG, Germany, March 10, 2010 /PRNewswire/ -- Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK).